Arrhythmias Pipeline Review, H2 2017 - Research and Markets

DUBLIN--()--The "Arrhythmias - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Arrhythmias - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Arrhythmias (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Arrhythmias (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Arrhythmias and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. Overview
  3. Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Arrhythmias - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Arrhythmias - Companies Involved in Therapeutics Development
  • Cynata Therapeutics Ltd
  • Gilead Sciences Inc
  • LATITUDE Pharmaceuticals Inc
  • Ono Pharmaceutical Co Ltd
  • Orion Oyj
  • SignPath Pharma Inc

For more information about this report visit https://www.researchandmarkets.com/research/nnw44c/arrhythmias

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Drugs